

*2011 Awards in*

# HEALTH OUTCOMES

application deadline: October 2010



“The funding I received from the PhRMA Foundation was an integral part of my research. It provided the resources necessary for the development of my project. Without this funding my research would not have progressed as it has.”

Tifni L. Preliou Williams, M.S.

# Area of Interest

## Health Outcomes Research

Outcomes research spans a broad spectrum of issues from studies evaluating the effectiveness of a particular pharmaceutical intervention to the impact of reimbursement policies on the outcomes of care. It also ranges from the development and use of tools to perform patient-based assessments to analyses of the best way to disseminate the results of outcomes research to providers or consumers to encourage behavior change.

Outcomes research incorporates a variety of research methods from various disciplines. The application of outcomes research principles in evaluating the design, delivery, and effectiveness of pharmaceuticals includes the following general areas:

Burden of Disease	Patient Satisfaction
Comparative Effectiveness Research	Patient Preferences
Compliance/Adherence	Pharmacoeconomics
Cost Consequences Analysis	Patient Reported Outcomes
Cost-Benefit Analysis	Psychometric Evaluation
Cost-Effectiveness Analysis	of Questionnaires (e.g. reliability, validity etc.)
Cost Utility Analysis	Research Methods
Health Outcomes Research	Symptom Measures
Health Related Quality of Life	Tolerability
Health Services Research	

## Pharmacoeconomics

Pharmacoeconomics involves evaluation of the behavior of individuals, organizations, and markets relevant to the use of pharmaceutical products, services, and programs. The discipline frequently focuses on the costs (inputs) and consequences (outcomes) of the use of pharmaceuticals.

## Patient Reported Outcomes

Patient Reported Outcomes deals with the value assigned to duration of life as modified by the impairment of physical, social, and psychological functional states, perceptions, and opportunities that are influenced by disease, injury, treatment, or policy. In this context, the field is also known as health-related quality of life (HRQOL).

### *on the cover*

Tifini L. Preliou Williams,  
M.S.

Purdue University,  
Department of  
Pharmacy Practice

Ms. Preliou Williams is  
a recipient of a 2009  
Pre Doctoral  
Fellowship in  
Health Outcomes

### *on the inside*

Jason Hurwitz, Ph.D.,  
Assistant Research  
Scientist

University of Arizona,  
Center for Health  
Outcomes and  
PharmacoEconomic  
Research

Dr. Hurwitz is a recipient  
of a 2009 Post Doctoral  
Fellowship in Health  
Outcomes

# Types of Awards

*The PhRMA Foundation Program(s) in Health Outcomes Research include the following awards:*

## **Pre Doctoral Fellowships**

This program provides two years of stipend funding during a student's Ph.D. doctoral program after course work has been completed and the remaining training activity is the student's research project. The applicant must be a full-time student and the Department Chair is expected to verify the applicant's doctoral candidacy.

## **Post Doctoral Fellowships**

This program provides stipend funding to well-trained graduates from Pharm.D., M.D., and Ph.D. programs who seek to further develop and refine their research skills through formal postdoctoral training. The application must include a research plan written by the applicant, the mentor's research record, and a description of how the mentored experience will enhance the applicant's career development in health outcomes research.

## **Sabbatical Fellowships**

This program provides stipend funding to enable faculty members at all levels with active research programs an opportunity to work at other institutions for periods of six months to one year to learn new skills or develop new collaborations that will enhance their research and research training activities in health outcomes. Applicants are expected to have approval (or pending approval) for a sabbatical leave from their home institution, and provide an endorsement from the mentor who will sponsor their visiting scientist activity. Matching funds must be provided through the university.

## **Research Starter Grants**

This program supports individuals beginning independent research careers in academia who do not have other substantial sources of research funding. Applicants must be appointed to an entry-level tenure-track or equivalent permanent position in a department or unit responsible for health outcomes research activities as part of its core mission. The description of an applicant's career goals and the Department Chair's description of institutional support for the applicant's salary are important in evaluating an application.

# General Information

## Eligibility Criteria

Before an individual is eligible to apply for a PhRMA Foundation award, an applicant must first have a firm commitment from a university in the U.S. Applications must be submitted from an accredited U.S. school, and all applicants must be U.S. citizens or permanent residents. Documentation is described under specific awards on the web site.

## Applications

Applications are to be submitted via the Foundation website. Required reports and hardcopies should be sent to: Eileen Cannon, Executive Director, Pharmaceutical Research and Manufacturers of America Foundation, 950 F Street, NW, Suite 300, Washington, DC 20004, and received by October 1, 2010. Applications will not be accepted after the deadline date.

Detailed application requirements are stated on our website. Please visit [www.phrmafoundation.org](http://www.phrmafoundation.org) to access an application and to view the specific requirements.

## Reports

The recipient school is expected to submit an annual report on the disposition of the funds awarded by the PhRMA Foundation. Any change in the relationship between the institution and the individual must be brought to the attention of the Foundation, at which time the situation will be reviewed.

A progress report is to be submitted by the awardee ten months into the first year of funding of the fellowship. The second year of funding, when applicable, is contingent upon a satisfactory review of the report. A final report is due within 60 days after the conclusion of the grant. These reports must be signed by the sponsor of the award recipient.

Any publications, speeches, presentations, and all other materials that stem directly from the research supported by this grant must acknowledge the support of the PhRMA Foundation. Three reprints of each publication should be forwarded to the PhRMA Foundation.

# Health Outcomes Programs



*Pharmaceutical research is a field on the cutting edge of science.*

It is purpose driven, intellectually challenging and socially rewarding. Rapid scientific advances—in biochemistry, molecular biology, cell biology, immunology, genetics, and information technology—are transforming drug discovery and development, paving the way for more effective, precise drugs that have fewer side effects and will benefit patients of all ages and stage of life. Over the past 45 years, the PhRMA Foundation has provided grants and fellowships to thousands of young scientists to further their careers in pharmaceutical research. Many have gone on to illustrious careers in academia and government, some have made major pharmaceutical discoveries and others have mentored scientists over their careers. The prestige of receiving a PhRMA Foundation award has enabled 80% of our awardees to go on to receive funding from larger institutions—proof of the status our awardees are accorded.

*Now the opportunities are greater than ever.*

**The PhRMA Foundation** supports young scientists at critical points in their careers in emerging, new, and traditional disciplines important to the pharmaceutical industry by awarding competitive fellowships and grants. Mid-career scientists may also receive sabbatical support when seeking to redirect their research efforts. The aim of these programs is to encourage young scientists who will be the research leaders of tomorrow to pursue careers in research and education in areas essential to drug discovery.

# General Information *continued*

## **Ethical Considerations**

The Scientific Advisory Committee as well as the program advisory committees of the PhRMA Foundation require the appropriate use of humans and animals in research. In their deliberations, these committees consider all aspects of a proposal and may deny support for many reasons. Careful consideration is given to human use and care of animals. For human and animal research, the project review committee requires a written statement confirming adherence to prevailing standards of ethical research practices, including institutional Review Board approval, before initiation of any research projects. In addition, assurance of informed consent is required for all research in which humans are involved.

## **Termination**

Circumstances may arise under which the school or the award recipient may wish to terminate the award before its completion. This may be arranged at any time by agreement between the school and the PhRMA Foundation. Termination will be made with the understanding that all unexpended funds will be returned to the PhRMA Foundation and that any unpaid balance of the award will be canceled.

## **Selection**

Selection of the recipients of the awards will be made by the Board of Directors of the PhRMA Foundation, based upon the recommendations of the Scientific Advisory Committee and the Health Outcomes Advisory Committee. All applicants will be notified no later than December 15, 2010.

### *Pharmaceutical Research and Manufacturers of America Foundation*

---

950 F Street, NW, Suite 300, Washington, D.C. 20004  
(202) 572-7756 • (202) 572-7799 fax

Please visit  
**[www.phrmafoundation.org](http://www.phrmafoundation.org)**  
to access an application and view the specific requirements.